Selecta Biosciences To Accelerate Program for Novel Dual Action Vaccine For Malaria

Grant from the Bill & Melinda Gates Foundation to Leverage Synthetic Nanoparticle Vaccine Platform to Enable Potent, Durable, Dual-Action Vaccines June 17, 2014 Selecta Biosciences, a¬†clinical stage¬†biotechnology company developing a novel class of targeted antigen-specific immune therapies, announced today that it has been awarded a $1.25 million grant from the Bill & Melinda Gates Foundation. The grant supports the research …